Drug Profile
Ilorasertib - AbbVie
Alternative Names: A-968660.0; Abbott-968660; ABT-348Latest Information Update: 25 Jul 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; National Cancer Institute (USA); University of Chicago; University of Texas M. D. Anderson Cancer Center
- Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules; Urea compounds
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Platelet-derived growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 11 Jul 2023 Discontinued - Phase-II for Solid tumours (Late-stage disease) in USA (PO) (NCT02478320)
- 11 Jul 2023 M.D. Anderson Cancer Center and AbbVie terminates a phase II trial in Solid tumours (Late-stage disease) in US (PO) due to company's decision to discontinue drug development (NCT02478320)
- 12 May 2022 M.D. Anderson Cancer Center and AbbVie completes a phase II trial in Solid tumours (Late-stage disease) in US (PO) (NCT02478320)